Neurocrine(NBIX) - 2023 Q3 - Earnings Call Transcript

Brian Abrahams Second, what weÂ're doing, as you can see and as weÂ'll be discussing at some length in our R&D Day is the investment in ourselves from a research standpoint. And thatÂ's going to be our transition of a company into multiple therapeutic modalities in the areas that we concentrate on, which is neuroscience, neuropsychiatry, neuroendocrinology and at some point in the very near future, neuroimmunology. If you think about the dynamics that I described earlier, with only about 20% of the eligible ...